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fusion. The treatment was designed with SmartArc with 
multiple arches made with Synergy. The dosage regimen used 
is Lagerwaard one: [RCT (20 Gy) + SIBmts (40 Gy)] / 5 frac. 
Positioning of the patient was checked daily with conebeam. 
Before starting the optimization we must be contoured 3mm 
ring around the calote we call follicles, and a contraction of 
the outer contour of 12mm we call volume CPE. We define 
two arcs (VMAT CCW 178 ° -60 ° and 300 ° -182 °), with the 
following objectives: follicles (DSEmax = 16 Gy, weight = 20; 
DSEmax = 5 Gy, weight = 1), brain-CPE (Dmax = 21Gy, weight 
= 100 and Dmin = 20 Gy, weight = 50), eyes (Dmax = 10 Gy, 
weight = 1). Later, we focus on separate metastases: 
optimization blocked prophylaxis (Optimization Type None) 
and create three structures: VI1 = PTV (MTS1) 5 mm VI2 = 
PTV (m2) 5 mm Epx = brain-VI1-VI2 . The objectives were 
PTVI (Dmax = 44Gy, despite Dmin = 100 and = 40 Gy weight = 
50), Epx (Dmax = 30 Gy) and brainstem (Dmax = 23Gy), 
follicles (DSEmax = 16 Gy, weight = 20 ; DSEmax = 5 Gy, 
weight = 1)  
Verifying treatment was performed with the Compass 
software, and the Matrixx detector with gamma (4%, 1 mm) 
conditioning. 
 
Results: So far we have treated 15 patients, the differences 
in the images of fusion of less than 1 mm and the average 
correction IGRT of 1.24mm. No acute toxicity. Nor alopecia, 
or temporary removal, 
 
Conclusion: If we consider our VMAT optimization alopecia in 
WBRT + SIB with eXaFrame and eXaSkin, produce optimal 
aesthetic results. 
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Purpose or Objective: To describe clinical outcomes of 
hypofractionated radiotherapy, either in combination or not 
with temozolomide (TMZ) in poor performance status 
glioblastoma (GBM) patients 
 
Material and Methods: We retrieved the charts of 96 patients 
treated with hypofractionated radiotherapy plus/minus TMZ 
for GBM at our Institution 
 
Results: Patients characteristics were summarized in Table 1.  
 
 
Among elderly patients, 38 (71.6%) were treated with RT 
alone, 9 patients (16.9%) with adjuvant TMZ, while 6 patients 
(11.3%) with a KPS ≥70 received hypoRT plus concurrent TMZ, 
followed by adjuvant chemotherapy in 3 (5.6%) of these 
cases. The median follow up time of the entire cohort was 
13.6 months (range 1-47 months). A significant improvement 
in KPS from baseline to the end of radiation therapy was 
observed in 73 patients (76%). The median overall survival 
time was 6.7 months, reducing to only 2.5 months and 4 
months respectively in elderly and younger patients with low 
performance status (KPS<70). The 6 months and 1 year 
survival rates were respectively 56.4% and 29.1%. In 
multivariate analysis, concomitant Temozolomide (HR:0.38, 
95% CI 0.16-0.85,p=.020) and adjuvant TMZ (HR:0.28,95% CI 
0.14-0.56,p=.000) emerged as significant indices of longer OS 
rates, while weaning from steroids (p=.18), extent of surgical 
resection (p=.17) and tumor site (p=.10) were not significant 
predictors of overall survival but showed a positive trend. 
Patients who received concomitant TMZ had a median 
survival time of 12.5 months compared with 6.3 months for 
those treated with RT alone (p=.017). Also the use of 
adjuvant chemotherapy resulted in improved survival 
compared to no sequential Temozolomide (10.8 vs 5.2 
months, p=.001). In the elderly cohort, patients treated with 
adjuvant TMZ had median OS of 8.15 months as opposed to 
6.4 months of those not receiving adjuvant chemotherapy 
(p=.001). A stronger impact of adjuvant TMZ has been 
reported in younger patients, with a median OS of 13.5 
months in adjuvant TMZ group compared to 3.7 months 
(p=.001) in the other group. Moreover, younger patients 
receiving concurrent Temozolomide showed a significantly 
longer OS of 20 months compared to 5.1 months in patients 
not having TMZ (p=.006). Acute tolerance to radiotherapy 
was generally good. No grade 3-4 acute toxicity was 
observed. 
 
Conclusion: Our findings seem to suggest that frail elderly 
patients with KPS at baseline < 70 do not benefit of an active 
treatment and could be carefully offered best supportive 
care. In the presence of a good functional status and a wide 
surgical resection, patients older than 65 years may take 
advantage of hypo-fractionated radiotherapy, followed by 
adjuvant TMZ. In younger patients with poor performance 
status, the significant survival gains obtained with combined 
modality treatment suggest that a maximum resection 
followed by combined radiation and chemotherapy should be 
recommended.  
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Purpose or Objective: Assessment of tolerance of combined 
modality therapy of patients with malignant gliomas 
irradiated using IMRT technique. We compared dose 
distribution in IMRT and conformal 3D treatment plans. 
 
Material and Methods: Between 2009 and 2013 in the 
Oncology Center in Krakow 60 patients with malignant 
gliomas received combined modality treatment. Mean age 
was 53 years (range 24–72 years). All patients were in good 
performance status (WHO 0–1). There were 48 patients with 
glioblastoma multiforme and 12 with anaplastic astrycytoma. 
48 patients underwent complete resection and 12 partial 
resection. Patient were irradiated using IMRT technique with 
a total dose of 60Gy in 30 fractions. All patients concurrently 
received temozolamide in the dose of 75mg/m2. In all 
patients we performed additional plans using 3D conformal 
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radiotherapy (3D-CRT) techniques and compared with IMRT 
plans. The 3D-CRT plans were prepared using 3–4 fields and 
IMRT plans consisted of 7–8 fields. The primary objective was 
to treat the planning target volume and to minimize the dose 
to organs at risk (OAR). Volumetric analysis, target coverage 
and conformity of prescribed doses were used in plan 
comparison.  
 
Results: Treatment tolerance was very good in all patients. 
Only 12 patients needed steroids during treatment. 
Adjustment of the dose distribution to the target volume was 
improved and the critical structures were better spared in 
the IMRT plans than in 3D-CRT plans. For all patients the 
mean dose and the maximum dose to OAR were significantly 
reduced in IMRT plans. With respect to target volume, IMRT 
technique reduced the maximum dose while increasing the 
minimum dose, resulting in improved conformity. In same 
patients with tumors located very close to OAR it was 
impossible to give 60Gy for target volume with 3D-CRT 
technique because of not acceptable doses in OAR. 
 
Conclusion: The IMRT technique combined with concurrent 
temozolamide is well tolerated and offers significant 
advantages comparing to 3D-CRT. Application of IMRT allows 
dose reduction at OAR without compromising target 
coverage. 
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Purpose or Objective: There is little consensus about the 
optimal treatment for low-grade glioma (LGG), and the 
clinical management of LGG is one of the most controversial 
areas in neurooncology. Radiation therapy is one option for 
treatment of patients with LGG whereas other options 
include postoperative observation. The aim of the study is to 
report the long-term follow-up of a cohort of adult patients 
with LGG post-operatively irradiated in one institution, and 
to identify prognostic factors for progression free survival. 
 
Material and Methods: Between 1975 and 2005, 180 patients 
with LGG (WHO II) received postoperative irradiation after 
non radical (subtotal or partial) excision. Patients had to be 
18 years of age or older, and have histologic proof of 
supratentorial fibrillary (FA), protoplasmic (PA) or 
gemistocytic astrocytoma (GA). Radiotherapy was given 
within 3 to 10 weeks after surgery. The treatment fields were 
localized and included the preoperative tumor volume, with 
a 1-2 cm margin, treated to a total dose of 50 to 60 Gy in 25 
to 30 fractions over 5 to 6 weeks. 
 
Results: Actuarial ten- year progression free survival ( APFS) 
in the whole group was 19% . The worse prognosis was 
reserved for patients with GA. Ten-year APFS rates for GA, 
PA and FA were 10%, 18% and 22% respectively. 
 
Conclusion: The findings from our long-term cohort of 180 
patients with LGG confirmed by uni- and multivariate analysis 
demonstrated that only astrocytoma histology significantly 
determined the prognosis. The best survival is reserved for 
patients with the fibrillary variant, and the worst for the 
gemistocytic one. 
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Purpose or Objective: To report preliminary results of re-
irradiation with proton therapy (PT) for large-volume 
recurrent high-grade gliomas (rHGG). 
 
Material and Methods: Between January and September 2015 
eight patients (pts) with rHGG (7 glioblastoma - GBM, 1 
anaplastic oligodendroglioma - AOD) were re-irradiated with 
PT. Age at re-irradiation was between 40 and 64 years while 
Karnofsky performance status was 60-100%. Minimum time 
between prior radiotherapy and PT was 8 months. Target 
definition was based on CT, MR, and 18F-DOPA PET imaging. 
GTV included any area of contrast enhancement at MR 
imaging after contrast medium administration plus any 
uptake regions at PET imaging. CTV was generated by adding 
to GTV a 3-mm uniform margin manually corrected in 
proximity of anatomical barriers. CTV was expanded by 4 mm 
to create PTV. PTV volume varied between 55 and 260 cc. 
The patient with AOD received 50.4 GyRBE in 28 fractions (fx) 
while GBM pts 36 GyRBE in 18 fx. Four GBM pts also received 
concomitant temozolomide (75 mg/m2/day, 7 days/week). 
All pts were treated with active beam scanning PT using 2-3 
fields with single field optimization technique.  
 
Results: All pts completed the treatment without breaks. 
Registered acute side effects (according to Common 
Terminology Criteria for Adverse Events versione 4.0) include 
skin erythema with pruritus, alopecia, fatigue, conjunctivitis, 
and headache. All the side effects were grade 1 or 2. There 
were no grade 3 or higher toxicities. One patient developed 
grade 1 neutropenia. Three pts started PT under steroids (2-8 
mg/day); two of them reduced the dose during PT, one kept 
the same steroids dose. None of remaining pts needed 
steroids therapy. During follow-up two pts developed 
radionecrosis (diagnosed at imaging) with mild symptoms 
controlled with steroids. All pts are alive. Four pts have 
stable disease one months after PT, three pts have stable 
disease three months after PT, and one pts progressed five 
months after PT. 
 
Conclusion: PT re-irradiation of large volume rHGG is 
feasible and safe even with concomitant chemotherapy 
administration. Longer follow-up is necessary to assess 
definitive efficacy.  
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Purpose or Objective: We evaluate the tolerance and 
efficiency of robotic hypo fractionated stereotactic 
radiotherapy (hSRT) for patients with Cavernous sinus 
meningiomas in our Institution. 
 
Material and Methods: We retrospectively reviewed patients 
who were treated with robotic hSRT for Cavernous sinus 
meningioma. Multidisciplinary staff approved treatment. A 
dose of 36 Gy was prescribed in 9 fractions. Treatment was 
delivered every other day.  
 
Results: Between 2010 and 2013, 18 evaluable patients with 
a total 18 lesions were treated in our institution with hSRT 
